Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7539963 | 0.83 | CHRNB2 (0.33) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL7911043 | 0.82 | CYP1A2 (0.36) | CYP1A2CYP2D6 | |
| SCHEMBL7911044 | 0.82 | CYP1A2 (0.36) | CYP1A2CYP2D6 | |
| SCHEMBL7995532 | 0.81 | CYP1A2 (0.38) | CYP1A2CYP2D6CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL7920214 | 0.79 | CYP1A2 (0.37) | CYP1A2CYP2D6 | |
| SCHEMBL7920217 | 0.79 | CYP1A2 (0.37) | CYP1A2CYP2D6 | |
| SCHEMBL20695818 | 0.78 | CYP1A2 (0.39) | CYP1A2CYP2D6 | |
| SCHEMBL9486764 | 0.74 | CYP1A2 (0.42) | CYP1A2CYP2D6 | |
| SCHEMBL11700916 | 0.74 | CYP1A2 (0.39) | CYP1A2CYP2D6 | |
| SCHEMBL5547886 | 0.74 | CA1 (0.50) | CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249702-A1 | CALCILYTIC COMPOUNDS | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | disclosed |
| US-7202261-B2 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-0901459-B1 | CALCILYTIC COMPOUNDS | NPS PHARMA INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050032850-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
| US-6818660-B2 | FOR INHIBITING CALCIUM RECEPTOR ACTIVIT; TO STIMULATE SECRETION OF PARATHYROID HORMONE (PTH); FOR BONE FORMATION | NPS PHARMACEUTICALS, INC. | 2004-11-16 | — | — | US | disclosed |
| US-6521667-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | disclosed |
| US-6432656-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020099220-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2002-07-25 | — | — | US | disclosed |
| US-6022894-A | Method of using calcilytic compounds | NPS PHARMACEUTICALS, INC. (US) | 2000-02-08 | — | — | US | disclosed |
| EP-0901459-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997037967-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032850-A1 | Calcilytic compounds | CALCR, CASR, ORAI1 | CYP1A2 4475/4885CYP2D6 4067/4885CHRNB2 2966/4885 |
| US-20070249702-A1 | CALCILYTIC COMPOUNDS | CALCR, CASR, ORAI1 | CYP1A2 4475/4885CYP2D6 4067/4885CHRNB2 2966/4885 |
| US-20020099220-A1 | Calcilytic compounds | CALCR, CASR, CALCRL | CYP1A2 4542/4885CYP2D6 3907/4885CHRNB2 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.